Results of Phase III Clinical Trial of Ibandronate Sodium Hydrate Oral Formulation, Bisphosphonate Antiresorptive Agent, in Japanese Patients with Osteoporosis Presented
Mar 30, 2015
Results of Phase III Clinical Trial of Ibandronate Sodium Hydrate Oral Formulation, Bisphosphonate Antiresorptive Agent, in Japanese Patients with Osteoporosis Presented
Results of Phase III Clinical Trial of Ibandronate Sodium Hydrate Oral Formulation, Bisphosphonate Antiresorptive Agent, in Japanese Patients with Osteoporosis Presented
